dimethyl 2-(2-nitrobenzyl)malonate | 859197-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl 2-(2-nitrobenzyl)malonate
• 英文别名: Dimethyl 2-(2-Nitrobenzyl)Malonate；dimethyl 2-[(2-nitrophenyl)methyl]propanedioate
• CAS: 859197-37-8
• 化学式: C₁₂H₁₃NO₆
• mdl: MFCD09859824
• 分子量: 267.238
• InChiKey: JTPCEKIPDRPTRV-UHFFFAOYSA-N

物化性质

• 熔点：
  40-42 °C
• 沸点：
  359.3±27.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  98.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  dimethyl 2-(2-nitrobenzyl)malonate 在 盐酸 作用下， 以 水 为溶剂， 以65 %的产率得到3-(2-硝基苯基)丙酸
  参考文献：
  名称：

  通过 SmI2 促进的 2-硝基苯乙酸还原合成羟吲哚

  摘要：

  首次报道了 SmI2 促进 2-硝基苯乙酸还原为羟吲哚的过程。该反应涉及硝基的还原，通过 N-O 键断裂并与邻近的羧基直接缩合进行。从合成的角度来看，开发了一种在温和中性条件下合成羟吲哚的新方法。

  DOI：

  10.1055/a-2175-1008
• 作为产物：
  描述：

  (2-nitro-benzyl)-malonic acid 生成 dimethyl 2-(2-nitrobenzyl)malonate
  参考文献：
  名称：

  Baker; Eccles, Journal of the Chemical Society, 1927, p. 2129

  摘要：

  DOI：

文献信息

• Novel <i>N</i>-transfer reagent for converting α-amino acid derivatives to α-diazo compounds
  作者：Guan-Han Lu、Tzu-Chia Huang、Hsiao-Chin Hsueh、Shin-Cherng Yang、Ting-Wei Cho、Ho-Hsuan Chou

  DOI：10.1039/d1cc01285a

  日期：——

  direct and effective transformation of α-amino ketones, acetamides, and esters to the corresponding α-diazo products under mild basic conditions has been developed. This one-step synthetic approach not only allows for generation of α-substituted-α-diazo carbonyl compounds from α-amino acid derivatives but also permits preparation of α-diazo dipeptides from N-terminal dipeptides (32 examples, up to 91%)

  开发了一种新型通用N-转移试剂，可在温和的碱性条件下直接有效地将 α-氨基酮、乙酰胺和酯转化为相应的 α-重氮产物。这种一步合成方法不仅允许从 α-氨基酸衍生物生成 α-取代-α-重氮羰基化合物，而且允许从N-末端二肽制备 α-重氮二肽（32 个例子，高达 91%） .
• Ring Size and Substitution Effects in the Tandem Reduction-Lactamization of<i>ortho</i>-Substituted Nitroarenes
  作者：Baskar Nammalwar、Richard A. Bunce、John T. Hiett

  DOI：10.1080/00304948.2015.1066643

  日期：2015.9.3

  Earlier work in this laboratory has explored the synthesis of heterocycles using tandem reaction strategies initiated under dissolving metal reduction conditions. The current investigation describes an evaluation of the scope of this process for the preparation of 2oxoindolines, 2-oxotetrahydroquinolines and 2-oxotetrahydro-1H-benzo[b]azepines. These moieties have value as synthetic building blocks, and

  该实验室的早期工作探索了使用在溶解金属还原条件下引发的串联反应策略合成杂环。目前的调查描述了对制备 2oxoindolines、2-oxotetrahydroquinolines 和 2-oxotetrahydro-1H-benzo[b] zepines 的过程范围的评估。这些部分具有作为合成构件的价值，并且是天然产物和生物活性化合物的常见结构组分。对文献的搜索揭示了制备这些化合物的方法数量有限，而且许多方法都存在严重的缺点，例如需要使用昂贵的试剂、产率低、大量竞争性副反应和有毒废物的产生。本研究报道的串联还原-内酰胺化序列，允许使用温和、高效且廉价的方法在短的 2-3 步序列中合成这些杂环。尽管这种方法过去已用于制备 2-氧代四氢喹啉，11-13,16 我们已将此策略扩展到其他环大小，扩展了可耐受的官能团列表，并评估了闭环成功。我们的工作从 2 的还原-内酰胺化开始，在溶解金属还原条件下得到
• Intramolecular Pd-Catalyzed Reductive Amination of Enolizable sp³-C–H Bonds
  作者：Russell L. Ford、Isabel Alt、Navendu Jana、Tom G. Driver

  DOI：10.1021/acs.orglett.9b03458

  日期：2019.11.1

  A palladium-catalyzed reductive cyclization of nitroarenes has been designed to construct sp3-C–NHAr bonds from sp3-C–H bonds by using an enolizable nucleophile to intercept a nitrosoarene intermediate. Exposure of ortho-substituted nitroarenes to 5 mol % of Pd(OAc)2 and 10 mol % of phenanthroline under 2 atm of CO constructs partially saturated 5-, 6-, or 7-membered N-heterocycles using α-pyridyl

  设计了钯催化的硝基芳烃还原环化反应，通过使用可烯化的亲核试剂拦截亚硝基芳烃中间体，从sp 3 -C H键构建sp 3 -C-NHAr键。在2个atm的CO构造下，使用α-吡啶基羧酸盐，丙二酸酯将邻位取代的硝基芳烃暴露于5 mol％的Pd（OAc）2和10 mol％的菲咯啉中，部分饱和的5、6或7元N-杂环，1，3-二甲基巴比妥酸，1，3-二酮或二呋喃作为亲核试剂。
• Selection, synthesis, and anti-inflammatory evaluation of the arylidene malonate derivatives as TLR4 signaling inhibitors
  作者：Shuting Zhang、Kui Cheng、Xiaohui Wang、Hang Yin

  DOI：10.1016/j.bmc.2012.08.022

  日期：2012.10

  Inhibition of TLR4 signaling is an important therapeutic strategy for intervention in the etiology of several pro-inflammatory diseases. There has been intensive research in recent years aiming to explore this strategy, and identify small molecule inhibitors of the TLR4 pathway. However, the recent failure of a number of advanced drug candidates targeting TLR4 signaling (e.g., TAK242 and Eritoran) prompted us to continue the search for novel chemical scaffolds to inhibit this critical inflammatory response pathway. Here we report the identification of a group of new TLR4 signaling inhibitors through a cell-based screening. A series of arylidene malonate analogs were synthesized and assayed in murine macrophages for their inhibitory activity against LPS-induced nitric oxide (NO) production. The lead compound 1 (NCI126224) was found to suppress LPS-induced production of nuclear factor-kappaB (NF-kappa B), tumor necrosis factor (TNF-alpha), interleukin-1 beta (IL-1 beta), and nitric oxide (NO) in the nanomolar-low micromolar range. Taken together, this study demonstrates that 1 is a promising potential therapeutic candidate for various inflammatory diseases. (C) 2012 Elsevier Ltd. All rights reserved.
• A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib
  作者：Juan F. Marquez Ruiz、Kinga Kedziora、Maria Pigott、Brian Keogh、Henry Windle、Jason Gavin、Dermot P. Kelleher、John F. Gilmer

  DOI：10.1016/j.bmcl.2013.01.060

  日期：2013.3

  Celecoxib is a COX-2 inhibitor drug that can be used to reduce the risk of colorectal adenocarcinoma. Glucocorticoids are used in the treatment of inflammatory bowel disease. A limitation to the use of both drug types is that they undergo absorption from the intestinal tract with serious side effects. The prodrug systems introduced here involve forming a nitro-substituted acylsulfonamide group in the case of celecoxib and a nitro-substituted 21-ester for the glucocorticoids. Drug release is triggered by the nitro reductase action of the colonic microflora, liberating a cyclization competent species. The release of the active parent drugs was evaluated in vitro using Clostridium perfringens and epithelial transport through Caco-2 monolayer evaluation was carried out to estimate the absorption properties of the prodrugs compared to the parental drugs. (C) 2013 Elsevier Ltd. All rights reserved.